Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Type 1 Diabetes (LIDO)
NCT01787916Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2013
- Primary completion
- Apr 2015
- Countries
- 1
- Sponsor
- CHU de Québec-Université Laval
- Modality
- Peptides
- Drugs
- liraglutide
- Conditions
- type 1 diabetes mellitus (T1D)
01
Overview
Phase 4, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Liraglutide First with Placebo First (2 arms). Primary endpoint: Glycated Hemoglobin A1c at 52 weeks. Started Apr 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Liraglutide First
Liraglutide then Placebo
Placebo First
Placebo then Liraglutide
03
Who it enrols
Adult patients with type 1 diabetes, overweight (BMI >= 25), and HbA1c < 8.5%, on basal/bolus insulin.
04
Endpoints
Primary
Glycated Hemoglobin A1c
Secondary
Abdominal Adipose Tissue
Beyond the preview
Go deeper on NCT01787916.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787916.